This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sultana, A. Articles by Ghaneh, P. Search for Related Content PubMed PubMed Citation Articles by Sultana, A. Articles by Ghaneh, P. Social Bookmarking                            What's this?

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

Asma Sultana, Catrin Tudur Smith, David Cunningham, Naureen Starling, John P. Neoptolemos, Paula Ghaneh

From the Cancer Research UK Liverpool Cancer Trials Unit and Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool; and Royal Marsden Hospital, Surrey, United Kingdom

Address reprint requests to Paula Ghaneh, MD, Division of Surgery and Oncology, School of Cancer Studies, 5th Floor–UCD Building, Daulby St, Liverpool, Merseyside L69 3GA, United Kingdom; e-mail: p.ghaneh{at}liv.ac.uk

Purpose There are a large number of randomized controlled trials involving chemotherapy in the management of advanced pancreatic cancer. Several chemotherapeutic agents, either alone or in combination with other chemotherapy or novel agents, have been used. The aim of these meta-analyses was to examine the different therapeutic approaches, and the comparisons examined were as follows: chemotherapy versus best supportive care; fluorouracil (FU) versus FU combination chemotherapy; gemcitabine versus FU; and gemcitabine versus gemcitabine combination chemotherapy.

Methods Relevant trials were identified by searching databases, trial registers, and conference proceedings. The primary end point was overall survival.

Results One hundred thirteen randomized controlled trials were identified, of which 51 trials involving 9,970 patients met the inclusion criteria. Chemotherapy improved survival compared with best supportive care (hazard ratio [HR] = 0.64; 95% CI, 0.42 to 0.98). FU-based combination chemotherapy did not result in better overall survival compared with FU alone (HR = 0.94; 95% CI, 0.82 to 1.08). There was insufficient evidence of a survival difference between gemcitabine and FU, but the wide CI includes clinically important differences in both directions, making a clear conclusion difficult (HR = 0.75; 95% CI, 0.42 to 1.31). Survival was improved after gemcitabine combination chemotherapy compared with gemcitabine alone (HR = 0.91; 95% CI, 0.85 to 0.97).

Conclusion There was a significant survival benefit for chemotherapy over best supportive care and gemcitabine combinations over gemcitabine alone. This supports the use of gemcitabine-based combination chemotherapy in the treatment of advanced pancreatic cancer.

Supported by Cancer Research UK.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. H. Kulke, M. A. Tempero, D. Niedzwiecki, D. R. Hollis, H. L. Kindler, M. Cusnir, P. C. Enzinger, S. M. Gorsch, R. M. Goldberg, and R. J. Mayer Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904 J. Clin. Oncol., November 20, 2009; 27(33): 5506 - 5512. [Abstract] [Full Text] [PDF]

				J. Tabernero and T. Macarulla Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development J. Clin. Oncol., November 20, 2009; 27(33): 5487 - 5491. [Full Text] [PDF]

				D. Cunningham, I. Chau, D. D. Stocken, J. W. Valle, D. Smith, W. Steward, P. G. Harper, J. Dunn, C. Tudur-Smith, J. West, et al. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5513 - 5518. [Abstract] [Full Text] [PDF]

				Y.-i. Yamashita, A. Taketomi, S. Itoh, N. Harimoto, E. Tsujita, K. Sugimachi, T. Gion, and Y. Maehara Phase II Trial of Gemcitabine Combined with 5-fluorouracil and Cisplatin (GFP) Chemotherapy in Patients with Advanced Biliary Tree Cancers Jpn. J. Clin. Oncol., September 20, 2009; (2009) hyp119v1. [Abstract] [Full Text] [PDF]

				M. J. Duffy, C. Sturgeon, R. Lamerz, C. Haglund, V. L. Holubec, R. Klapdor, A. Nicolini, O. Topolcan, and V. Heinemann Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report Ann. Onc., September 8, 2009; (2009) mdp332v2. [Abstract] [Full Text] [PDF]

				S. Laurent, E. Monsaert, T. Boterberg, A. Demols, I. Borbath, M. Polus, A. Hendlisz, B. de Hemptinne, C. Mahin, P. Scalliet, et al. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study Ann. Onc., August 1, 2009; 20(8): 1369 - 1374. [Abstract] [Full Text] [PDF]

				E. Van Cutsem, W. L. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J.-L. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert, et al. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2231 - 2237. [Abstract] [Full Text] [PDF]

				B. R. Tan, W. S. Brenner, J. Picus, S. Marsh, F. Gao, C. Fournier, P. M. Fracasso, J. James, J. L. Yen-Revollo, and H. L. Mcleod Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies Ann. Onc., October 1, 2008; 19(10): 1742 - 1748. [Abstract] [Full Text] [PDF]

				T. B. Brunner, M. Geiger, G. G. Grabenbauer, M. Lang-Welzenbach, T. S. Mantoni, A. Cavallaro, R. Sauer, W. Hohenberger, and W. G. McKenna Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer J. Clin. Oncol., June 1, 2008; 26(16): 2699 - 2706. [Abstract] [Full Text] [PDF]

				A. F. Hezel and A. X. Zhu Systemic Therapy for Biliary Tract Cancers Oncologist, April 1, 2008; 13(4): 415 - 423. [Abstract] [Full Text] [PDF]